Double Outlet Right Ventricle: Comprehensive Disease-Characteristics Report

Executive summary

Double outlet right ventricle (DORV) is a congenital ventriculoarterial connection phenotype in which both great arterial roots arise predominantly from the morphologic right ventricle. It is not one uniform disease: physiology, clinical presentation, operation, and prognosis depend principally on the ventricular septal defect (VSD), its relationship to the arterial roots, great-artery orientation, outflow obstruction, ventricular adequacy, and associated cardiac or extracardiac abnormalities. A 2024 review estimates that DORV constitutes 1–3% of congenital heart disease (CHD) and occurs in approximately 3–9 per 100,000 live births. (moscatelli2024importanceofcardiovascular pages 8-10)

The strongest current model is multifactorial developmental causation. Human and experimental evidence implicates chromosomal abnormalities, rare sequence variants, cilia/left–right patterning, second-heart-field and cardiac-neural-crest development, noncanonical Wnt/planar-cell-polarity signaling, actomyosin organization, and tightly regulated retinoic-acid signaling. No single gene accounts for most cases. Treatment is individualized anatomical reconstruction—usually biventricular repair when feasible—or staged single-ventricle palliation when two-ventricle circulation cannot be constructed safely.

The following evidence table distinguishes DORV-specific findings from broader CHD evidence used to inform testing or management.

Table: This table summarizes DORV-specific facts and carefully separated general CHD evidence relevant to a disease knowledge-base entry. It highlights anatomic determinants, imaging, genetics, developmental mechanisms, treatment planning, and model systems while avoiding unsupported lesion-specific claims.

1. Disease information

Definition and classification

DORV is best regarded as a morphologic descriptor, not a single physiologic entity. Both great arteries arise primarily from the right ventricle, and the left ventricle ejects through a VSD. Classification should document:

1. VSD relationship: subaortic, subpulmonary, doubly committed/juxtaarterial, or remote/noncommitted.
2. Great-artery relationship and conal anatomy.
3. Pulmonary or systemic outflow obstruction.
4. Ventricular size and atrioventricular-valve anatomy.
5. Coronary anatomy, arch disease, heterotaxy, and other associated lesions.

The clinically relevant VSD is often a curved three-dimensional communication; its borders determine whether a patch or tunnel can direct left-ventricular blood to an arterial root without obstructing inflow, outflow, or conduction tissue. (spicer2014ventricularseptaldefect pages 1-2)

Identifiers and synonyms

• MeSH: Double Outlet Right Ventricle, D004310. (NCT00972608 chunk 1)
• ICD-10-CM: Q20.1, Double outlet right ventricle.
• ICD-11: classified among congenital anomalies of ventriculoarterial connections; local coding-browser verification is advised before database ingestion because extension codes vary by release.
• MONDO: DORV is represented in MONDO, but the exact release-specific identifier should be verified through the current MONDO API before production use.
• OMIM: no single unitary OMIM disorder adequately represents nonsyndromic DORV; OMIM entries are generally gene- or syndrome-specific.
• Common names: DORV, double-outlet right ventricle, double outlet of right ventricle. Historical physiologic labels include Taussig–Bing anomaly for a subpulmonary-VSD/DORV phenotype.

This report synthesizes aggregated disease-level resources, cohorts, reviews, clinical-trial records, and primary experimental studies. It is not derived from one patient’s EHR.

2. Etiology, risk, and protective factors

Causal architecture

DORV results from disturbed embryonic alignment and septation of the ventricular outlets. Etiology is heterogeneous:

• Chromosomal/CNV: aneuploidies and pathogenic copy-number variants, including syndromic conotruncal disease, are important.
• Monogenic/oligogenic: variants affecting transcription, chromatin, cilia, laterality, second-heart-field, neural-crest, and cytoskeletal pathways can produce DORV.
• Multifactorial: many isolated cases remain unexplained and probably reflect combinations of rare/common variants, developmental stochasticity, and maternal/environmental influences.

General CHD evidence—not a DORV-specific yield—suggests a genetic cause in 20–30% of affected patients. In a 525-neonate CHD cohort, CMA found pathogenic CNVs in 21.3% (61/287) of those tested; karyotype/FISH identified aneuploidy in another 11% (58/525) of the overall cohort, and conotruncal lesions had a 27.2% CMA yield. These figures support genetic evaluation in complex DORV but must not be presented as DORV-specific estimates. (findley2022congenitalheartdefects pages 1-2)

Environmental and maternal risks

Recent CHD-level literature identifies maternal diabetes, obesity, phenylketonuria, smoking, alcohol, retinoids such as isotretinoin, thalidomide, selected antiseizure drugs, some antiretrovirals, and exposure to pesticides, dioxins, or polychlorinated biphenyls as possible teratogenic risks. Lesion-specific effect sizes for DORV are generally unavailable; causality must not be assigned to an individual exposure solely because DORV occurred. (shorbaji2024currentgeneticmodels pages 1-2)

Retinoic acid is particularly biologically plausible: it is both a morphogen and teratogen, and excessive or deficient signaling disturbs cardiac development in dose- and stage-dependent fashion. (nakajima2019retinoicacidsignaling pages 1-2)

Protective factors and gene–environment interaction

No reproducible DORV-specific protective allele, diet, supplement, or lifestyle factor is established. General preconception measures—glycemic control, management of phenylketonuria, folate sufficiency, avoidance of known teratogens, smoking cessation, medication review, and rubella immunization—reduce broader congenital-anomaly risk but do not guarantee prevention of DORV. Retinoid biology illustrates gene–environment interaction: variants in synthesis, degradation, receptor, or downstream developmental pathways could plausibly alter sensitivity to maternal retinoid exposure, although clinically validated DORV-specific interaction estimates are lacking.

3. Phenotypes

Presentation ranges from critical neonatal cyanosis to pulmonary overcirculation and heart failure. Frequency is anatomy-dependent, so universal percentages are inappropriate.

• DORV anatomy: congenital, invariant structural sign; HPO Double outlet right ventricle (HP:0001719).
• VSD/interventricular communication: essentially integral to viable LV egress; HPO Ventricular septal defect (HP:0001629).
• Cyanosis/hypoxemia: neonatal or infantile, particularly with pulmonary stenosis/atresia, unfavorable streaming, or parallel circulations; severity variable; HPO Cyanosis (HP:0000961).
• Tachypnea, feeding difficulty, diaphoresis, failure to thrive: arise with excessive pulmonary flow or heart failure; usually progressive over weeks without treatment; HPO terms include Tachypnea (HP:0002789), Feeding difficulties (HP:0011968), and Failure to thrive (HP:0001508).
• Cardiac murmur: variable and determined by VSD/outflow obstruction; HPO Cardiac murmur (HP:0030148).
• Pulmonary stenosis/atresia: produces reduced pulmonary flow and cyanosis; HPO Pulmonary stenosis (HP:0001642) or Pulmonary atresia (HP:0004935).
• Pulmonary hypertension: downstream of a large unrestricted pulmonary circuit if repair is delayed; HPO Pulmonary hypertension (HP:0002092).
• Associated phenotypes can include TGA-type arterial relationships, atrioventricular-valve abnormalities, ventricular hypoplasia, aortic arch anomalies, dextrocardia, situs abnormalities/heterotaxy, and extracardiac syndromic findings.

Quality of life is shaped less by the label DORV than by repair type, residual obstruction or regurgitation, ventricular function, arrhythmia, exercise capacity, neurodevelopment, repeated procedures, and—after Fontan palliation—multisystem Fontan morbidity. Complex CHD survivors are at increased neurodevelopmental risk through genetic disease, altered fetal oxygen delivery, perioperative injury, repeated hospitalization, and socioeconomic stressors. (findley2022congenitalheartdefects pages 1-2, corno2023narrativereviewof pages 1-2)

4. Genetic and molecular information

Genes and variants

There is no definitive short list of genes that explains most isolated DORV. Reported or mechanistically supported genes include FOXJ1, SHROOM3, CHD7, TBX1, NKX2-5, GATA4/GATA6, ZFPM2, NOTCH-pathway genes, NODAL-pathway genes, and numerous ciliary/chromatin genes. Associations range from established syndromic causation to candidate-level evidence; each variant requires gene–disease and ACMG/AMP assessment.

A particularly informative 2023 primary study reported a truncating FOXJ1 c.784_799dup; p.Glu267Glyfs*12 variant identified by clinical exome sequencing in a patient with atrial and ventricular septal defects, DORV, and TGA. The mutant failed to induce ectopic cilia in frog epidermis or activate an ADGB promoter assay, while Foxj1-loss mice developed randomized looping and complex defects including DORV. The authors concluded: “These results indicate that pathogenic variants in FOXJ1 can cause isolated CHD.” This is compelling human-plus-functional evidence but still represents a rare cause, not a common DORV gene. Published 9 May 2023; DOI: https://doi.org/10.1093/hmg/ddad065. (padua2023congenitalheartdefects pages 1-2)

Variant classes reported across DORV-associated disorders include germline missense, nonsense, frameshift, splice, CNV, and aneuploid variants. Population frequency should be checked against ancestry-matched gnomAD data; a credible highly penetrant severe-developmental allele is usually absent or extremely rare. Somatic mutation is not an established general cause of DORV.

Chromosomal and epigenetic abnormalities

Relevant abnormalities include aneuploidies and pathogenic CNVs such as 22q11.2-region disease in the broader conotruncal differential. Chromatin regulators can cause syndromic CHD, but no DORV-specific methylation signature is clinically validated. Histone regulation is mechanistically relevant to second-heart-field transcription, yet clinical epigenomic testing is not routine.

Modifiers, penetrance, and inheritance

Inheritance depends on the diagnosis: de novo autosomal-dominant variants are common in severe syndromic CHD; inherited AD, AR, X-linked, and oligogenic mechanisms also occur. Penetrance and expressivity are often incomplete and variable. Anticipation, a general founder effect, and a single carrier frequency are not established for DORV as a phenotype. Recurrence counseling must therefore use the identified syndrome/gene when available; otherwise, empiric CHD-family recurrence estimates are used.

5. Environmental information

DORV is not infectious, contagious, occupationally acquired after birth, or lifestyle-induced in the affected infant. Maternal metabolic disease, medication/teratogen exposure, and environmental toxicants are relevant during early embryogenesis. No pathogen is established as a specific cause, although maternal infections such as rubella are recognized general CHD risks. Exposure ascertainment should be prospective where possible because retrospective recall and confounding are major limitations.

6. Mechanism and pathophysiology

Causal developmental chain

1. Upstream disturbance: genetic/CNV/teratogenic perturbation affects laterality, cardiac progenitor specification, neural-crest migration, second-heart-field addition, or cytoskeletal polarity.
2. Morphogenesis: abnormal heart-tube looping, outflow elongation, conal rotation/alignment, and outlet septation leave both arterial roots supported predominantly by the right ventricle.
3. Anatomic routing defect: the LV can reach an arterial root only through the VSD.
4. Hemodynamic phenotype: VSD position and resistance/obstruction determine systemic-versus-pulmonary streaming, cyanosis, pulmonary overcirculation, ventricular pressure load, and heart failure.
5. Downstream injury: chronic hypoxemia, pulmonary vascular remodeling, ventricular hypertrophy/dysfunction, arrhythmia substrate, and postoperative scar/conduit/valve disease.

Major pathways and cells

• Noncanonical Wnt/planar-cell-polarity–actomyosin pathway: Shroom3 gene-trap mice show variable VSD, DORV, and thin LV myocardium. SHROOM3 is expressed in ventricular cardiomyocytes, cardiac neural crest, and second-heart-field cells and acts downstream of DVL2; loss disrupts actomyosin organization, polarity, proliferation, and morphology. DOI: https://doi.org/10.1016/j.ydbio.2020.05.013. (durbin2020shroom3isdownstream pages 1-7)
• Motile cilia–NODAL laterality: FOXJ1-dependent cilia generate leftward organizer flow; disruption randomizes looping and great-artery position. (padua2023congenitalheartdefects pages 1-2)
• Retinoic-acid signaling: correctly bounded RA signaling maintains/differentiates second-heart-field progenitors required for outflow elongation and septation. (nakajima2019retinoicacidsignaling pages 1-2)
• Cardiac neural crest and second heart field: defective migration, proliferation, or integration impairs conotruncal septation/alignment.

Suggested annotations: GO heart development, cardiac chamber morphogenesis, outflow tract morphogenesis, determination of left/right symmetry, cilium movement, planar cell polarity pathway, actomyosin structure organization, and retinoic-acid receptor signaling. Suggested cell types are cardiomyocyte, cardiac neural crest cell, second-heart-field cardiac progenitor, endocardial cell, vascular smooth-muscle cell, and ciliated organizer cell. Suitable CL identifiers should be release-validated because some developmental cardiac-cell terms remain ontology-dependent.

No DORV-specific reproducible plasma metabolomic, proteomic, lipidomic, or immune signature is established. Inflammation is downstream of surgery or heart failure rather than a primary mechanism.

7. Anatomical structures affected

Primary structures are the morphologic right and left ventricles, ventricular septum, conal/outflow myocardium, aortic and pulmonary roots, semilunar valves, and proximal great arteries. Secondary involvement may include atrioventricular valves, coronary arteries, pulmonary arteries, aortic arch, conduction tissue, lungs/pulmonary vasculature, liver and lymphatics after Fontan circulation, and brain through altered oxygen delivery.

Suggested UBERON annotations: heart, right ventricle, left ventricle, interventricular septum, cardiac outflow tract, ascending aorta, pulmonary trunk, aortic valve, and pulmonary valve. Relevant subcellular compartments include motile cilium/axoneme, nucleus/chromatin, adherens/cytoskeletal structures, actomyosin cortex, and extracellular matrix. DORV itself is not lateralized, but associated situs and dextrocardia can be.

8. Temporal development

The lesion forms during early embryonic cardiogenesis and is therefore congenital and non-remitting. Structural heart development is substantially established in the first trimester; fetal imaging commonly recognizes major CHD during the second trimester. A 2023 review reported that most malformations are recognizable at 16–18 weeks, with sensitivity above 96% and specificity approaching 100% in the cited specialist-imaging literature, although these are not DORV-specific population-screening values. (corno2023narrativereviewof pages 1-2)

Clinical onset is variable: critical cyanosis may occur immediately after birth; pulmonary-overcirculation symptoms often emerge as pulmonary vascular resistance falls over days to weeks. Without definitive management, physiology may progress to severe cyanosis, heart failure, growth failure, or irreversible pulmonary vascular disease. After repair, DORV becomes a lifelong repaired CHD requiring surveillance rather than a cured developmental predisposition.

9. Inheritance and population

DORV incidence is approximately 3–9/100,000 live births, representing 1–3% of CHD. (moscatelli2024importanceofcardiovascular pages 8-10) No consistent sex ratio, ethnic restriction, endemic region, founder variant, or age-dependent prevalence can be assigned confidently from the retrieved DORV-specific evidence. Apparent geographic variation is affected by prenatal detection, pregnancy outcome, registry definitions, access to echocardiography, and surgical referral.

The phenotype is usually sporadic and multifactorial. If a molecular diagnosis is found, inheritance follows that disorder. Germline mosaicism is possible for apparently de novo variants but has not been quantified for DORV overall. Consanguinity becomes relevant when an AR syndrome or laterality disorder is suspected.

10. Diagnostics

Clinical and imaging diagnosis

Fetal echocardiography can identify both arteries arising from the right ventricle, VSD position, great-artery relationship, outflow obstruction, ventricular balance, arch anatomy, rhythm, and extracardiac markers. Postnatally, transthoracic echocardiography is first-line. ECG, pulse oximetry, chest radiography, blood gases, lactate, and routine laboratory studies assess physiology but are not diagnostic biomarkers.

CMR supplies ventricular volumes/function, flow, VSD-to-artery spatial relationships, great-vessel anatomy, and postoperative assessment without ionizing radiation. The 2024 review states that preoperative CMR is valuable for detailed VSD and spatial visualization; 4D flow can characterize RVOT dimensions and flow dynamics. CT is useful when high spatial resolution, airway, coronary, or rapid acquisition is needed. Catheterization is reserved for unresolved anatomy, intervention, coronary/hemodynamic questions, or pulmonary vascular resistance assessment. (moscatelli2024importanceofcardiovascular pages 8-10)

Patient-specific reconstruction is already implemented in research and selected centers. NCT00972608, a completed prospective case-only study enrolling 66 patients up to age 22, used MRI, CT, or 3D echocardiography for virtual reconstruction and simulated operations in complex lesions including DORV. ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT00972608. (NCT00972608 chunk 1)

Genetic-testing strategy

1. Clinical genetics examination and three-generation pedigree.
2. Rapid karyotype/FISH or rapid genomic testing when aneuploidy or 22q11.2 disease is strongly suspected.
3. CMA for complex DORV, extracardiac anomalies, developmental differences, or no recognizable syndrome.
4. Trio CHD/laterality panel or trio exome sequencing after nondiagnostic CMA; genome sequencing may add noncoding, balanced structural, and complex CNV detection.
5. Mitochondrial or targeted testing only when phenotype indicates it. Repeat-expansion and tumor/somatic testing are not routine.

Variants should be classified under ACMG/AMP criteria using ClinVar/ClinGen and population databases. Exome interpretation remains challenging; functional validation and periodic reanalysis are valuable. (yasuhara2021geneticsofcongenital pages 9-10)

Differential diagnosis

Distinguish DORV from tetralogy of Fallot, d-TGA with VSD, overriding aorta not meeting DORV criteria, pulmonary atresia/VSD, truncus arteriosus, congenitally corrected TGA, single-ventricle lesions, and complex heterotaxy. The key discriminator is segmental anatomy and the degree of arterial-root commitment to each ventricle, not physiology alone.

11. Outcome and prognosis

There is no scientifically defensible single DORV survival rate because morphology and surgical pathway differ profoundly. Favorable factors include two adequate ventricles, a routable VSD, preserved ventricular/atrioventricular-valve function, absence of major extracardiac syndrome, and repair before pulmonary vascular disease. Risk rises with remote VSD, ventricular imbalance, heterotaxy, pulmonary atresia, coronary/arch complexity, genetic syndromes, prematurity, and Fontan dependence.

Long-term complications include residual/recurrent LV or RV outflow obstruction, conduit stenosis/regurgitation, semilunar-valve disease, ventricular dysfunction, arrhythmia, heart block, endocarditis, reoperation, exercise limitation, and neurodevelopmental or psychosocial morbidity. Fontan patients additionally face venous hypertension, liver disease, lymphatic failure, protein-losing enteropathy, thrombosis, and eventual Fontan failure. Lifelong adult-congenital-heart-disease follow-up is essential. CMR is particularly useful for detecting late structural and functional complications. (moscatelli2024importanceofcardiovascular pages 8-10)

12. Treatment

Anatomy-driven strategy

• Neonatal stabilization: oxygen only as physiologically appropriate; ventilation, diuretics/inotropes for heart failure; prostaglandin E1 for duct-dependent pulmonary or systemic flow; atrial septostomy when mixing is inadequate in TGA-like physiology.
• Subaortic VSD without pulmonary stenosis: intraventricular tunnel from LV through VSD to aorta, with closure/rerouting tailored to anatomy.
• Subpulmonary VSD/Taussig–Bing physiology: commonly arterial switch plus VSD-to-pulmonary-root routing, with arch repair when required.
• DORV with pulmonary stenosis/atresia: Rastelli-type LV-to-aorta tunnel with RV–PA conduit, REV, Nikaidoh/root-translocation strategies, or other individualized reconstruction.
• Remote/noncommitted VSD: complex tunnel, VSD enlargement, root translocation, staged ventricular recruitment, or single-ventricle palliation depending on obstruction and ventricular geometry.
• Unbalanced ventricles/unsafe biventricular route: staged palliation—systemic/pulmonary flow control, bidirectional Glenn, then Fontan completion.

No drug corrects DORV anatomy, and there is no approved DORV-specific gene, RNA, cell, targeted, or immunotherapy. Pharmacotherapy is supportive. Rehabilitation includes nutrition, developmental surveillance, physical activity counseling, school support, and cardiac rehabilitation where indicated. Suggested NCIT intervention concepts include cardiac surgical procedure, ventricular septal-defect repair, arterial switch operation, Rastelli procedure, cavopulmonary shunt, Fontan procedure, cardiac catheterization, prostaglandin E1 therapy, diuretic therapy, and cardiac transplantation.

Recent innovation focuses on CMR/CT-based 3D reconstruction, virtual reality, 3D printing, computational flow, and individualized tunnel design rather than a new disease-modifying drug. (moscatelli2024importanceofcardiovascular pages 8-10, NCT00972608 chunk 1)

13. Prevention

Primary prevention: most DORV cannot presently be prevented. Preconception genetic counseling, control of diabetes/phenylketonuria, avoidance of isotretinoin and other established teratogens, medication review, smoking/alcohol avoidance, folate sufficiency, and recommended vaccination are prudent general measures.

Secondary prevention: prenatal anomaly screening and fetal echocardiography do not prevent formation but enable genetic testing, counseling, delivery planning, and immediate neonatal care. Prenatal recognition of complex CHD supports coordinated delivery at a tertiary cardiac center. (corno2023narrativereviewof pages 1-2)

Tertiary prevention: timely repair before pulmonary vascular disease, endocarditis prevention according to current high-risk guidelines, immunization, dental hygiene, thrombosis management where indicated, home monitoring after staged palliation, neurodevelopmental screening, and lifelong imaging reduce complications. Cascade testing is appropriate only when a familial pathogenic variant or chromosome disorder is identified. Preimplantation or prenatal diagnosis can then be offered, recognizing variable expressivity.

14. Other species and natural disease

DORV-like congenital malformations can occur sporadically in veterinary species, but the retrieved evidence did not establish a common naturally occurring, breed-specific syndrome or zoonotic relevance. It is noninfectious and nontransmissible. Comparative value lies primarily in experimentally induced or genetically engineered models rather than natural animal disease.

Relevant taxa include Mus musculus (NCBI Taxon 10090), Danio rerio (7955), Xenopus species, chick, and human iPSC-derived cardiac systems. Orthologs of FOXJ1, SHROOM3, DVL, NODAL, and RA-pathway genes are evolutionarily conserved.

15. Model organisms

• Shroom3 gene-trap mouse: reproduces VSD, DORV, and thin LV myocardium with variable penetrance; useful for PCP, actomyosin, neural-crest, second-heart-field, and cardiomyocyte-polarity studies. Limitation: developmental lethality and species-specific anatomy. (durbin2020shroom3isdownstream pages 1-7)
• Foxj1-loss mouse: randomized looping, dextrocardia/abnormal looping, AVSD, DORV, single ventricle, and abnormal great-artery position; strong model for motile cilia and left–right patterning. (padua2023congenitalheartdefects pages 1-2)
• Zebrafish/Xenopus: rapid, accessible embryos support cilia, laterality, second-heart-field, and CRISPR studies. Limitations include two-chambered zebrafish anatomy, gene duplication, and imperfect antibody/tool transfer.
• Chick: valuable for neural-crest ablation, lineage tracing, and hemodynamic manipulation, but genetic resources and human correspondence are less complete.
• Human iPSC/cardiac organoid systems: permit patient-variant editing and cell-autonomous assays; limitations include immaturity, incomplete three-dimensional outflow anatomy, genomic instability, and inability to reproduce maternal–placental circulation. A 2024 review emphasizes that model choice must match the question; no single platform reproduces the full human DORV phenotype. DOI: https://doi.org/10.6026/973206300200415. (shorbaji2024currentgeneticmodels pages 1-2)

Evidence appraisal and key gaps

The most authoritative recent DORV-specific evidence retrieved was a 2024 CMR review and the 2023 FOXJ1 human/functional study. Primary DORV cohorts remain heterogeneous in nomenclature, era, anatomy, and operation, limiting pooled survival or phenotype-frequency estimates. There is no validated DORV-specific biomarker, molecular signature, protective factor, pharmacogenomic rule, or disease-modifying medical therapy. Genomic yields quoted above are principally from broader CHD/conotruncal cohorts and must be labeled accordingly. Several retrieved records supplied DOI and publication date but not PMID; therefore, DOI URLs are reported rather than inventing unverified PMID values.

References

1. (moscatelli2024importanceofcardiovascular pages 8-10): Sara Moscatelli, Alice Pozza, Isabella Leo, Jessica Ielapi, Alessandra Scatteia, Sofia Piana, Annachiara Cavaliere, Elena Reffo, and Giovanni Di Salvo. Importance of cardiovascular magnetic resonance applied to congenital heart diseases in pediatric age: a narrative review. Children, 11:878, Jul 2024. URL: https://doi.org/10.3390/children11070878, doi:10.3390/children11070878. This article has 17 citations.

2. (shorbaji2024currentgeneticmodels pages 1-2): Ayat Shorbaji, Peter Natesan Pushparaj, Sherin Bakhashab, Ayat B Ayat B Al-Ghafari, Rana R Al-Rasheed, Loubna Siraj Mira, Mohammad Abdullah Basabrain, Majed Alsulami, Isam M. Abu Zeid, Muhammad Imran Naseer, and Mahmood Rasool. Current genetic models for studying congenital heart diseases: advantages and disadvantages. Bioinformation, 20:415-429, May 2024. URL: https://doi.org/10.6026/973206300200415, doi:10.6026/973206300200415. This article has 1 citations.

3. (NCT00972608 chunk 1): Timothy Slesnick. Surgical Planning for Reconstruction of Complex Heart Defects. Emory University. 2009. ClinicalTrials.gov Identifier: NCT00972608

4. (findley2022congenitalheartdefects pages 1-2): Tina O. Findley, Alyssa K. Crain, Smridhi Mahajan, Ahmed Deniwar, Jessica Davis, Ana S. Solis Zavala, Antonio F. Corno, and David Rodriguez‐Buritica. Congenital heart defects and copy number variants associated with neurodevelopmental impairment. American Journal of Medical Genetics Part A, 188:13-23, Sep 2022. URL: https://doi.org/10.1002/ajmg.a.62484, doi:10.1002/ajmg.a.62484. This article has 19 citations.

5. (yasuhara2021geneticsofcongenital pages 9-10): Jun Yasuhara and Vidu Garg. Genetics of congenital heart disease: a narrative review of recent advances and clinical implications. Translational Pediatrics, 10:2366-2386, Sep 2021. URL: https://doi.org/10.21037/tp-21-297, doi:10.21037/tp-21-297. This article has 130 citations and is from a peer-reviewed journal.

6. (durbin2020shroom3isdownstream pages 1-7): Matthew D. Durbin, James O’Kane, Samuel Lorentz, Anthony B. Firulli, and Stephanie M. Ware. Shroom3 is downstream of the planar cell polarity pathway and loss-of-function results in congenital heart defects. Developmental Biology, 464:124-136, Aug 2020. URL: https://doi.org/10.1016/j.ydbio.2020.05.013, doi:10.1016/j.ydbio.2020.05.013. This article has 42 citations and is from a peer-reviewed journal.

7. (padua2023congenitalheartdefects pages 1-2): Maria B Padua, Benjamin M Helm, John R Wells, Amanda M Smith, Helen M Bellchambers, Arthi Sridhar, and Stephanie M Ware. Congenital heart defects caused by foxj1. Human molecular genetics, 32:2335-2346, May 2023. URL: https://doi.org/10.1093/hmg/ddad065, doi:10.1093/hmg/ddad065. This article has 21 citations and is from a domain leading peer-reviewed journal.

8. (nakajima2019retinoicacidsignaling pages 1-2): Yuji Nakajima. Retinoic acid signaling in heart development. genesis, Jul 2019. URL: https://doi.org/10.1002/dvg.23300, doi:10.1002/dvg.23300. This article has 58 citations and is from a peer-reviewed journal.

9. (corno2023narrativereviewof pages 1-2): Antonio F. Corno, Tina O. Findley, and Jorge D. Salazar. Narrative review of single ventricle: where are we after 40 years? Translational Pediatrics, 12:221-244, Feb 2023. URL: https://doi.org/10.21037/tp-22-573, doi:10.21037/tp-22-573. This article has 25 citations and is from a peer-reviewed journal.

10. (spicer2014ventricularseptaldefect pages 1-2): Diane E Spicer, Hao H Hsu, Jennifer Co-Vu, Robert H. Anderson, and F. J. Fricker. Ventricular septal defect. Orphanet Journal of Rare Diseases, Dec 2014. URL: https://doi.org/10.1186/s13023-014-0144-2, doi:10.1186/s13023-014-0144-2. This article has 130 citations and is from a peer-reviewed journal.

Artifacts

• Edison artifact artifact-00